Summary of OGC dose during the 24-month follow-up period
| Follow-up period | ||||
|---|---|---|---|---|
| 6 months post-index | 12 months post-index | 18 months post-index | 24 months post-index | |
| OGC dose threshold, mg/day, n (%) | ||||
| N* | 501 | 410 | 346 | 299 |
| ≤10 | 440 (87.8) | 383 (93.4) | 324 (93.6) | 292 (97.7) |
| ≤7.5 | 345 (68.9) | 330 (80.5) | 294 (85.0) | 280 (93.6) |
| ≤5 | 308 (61.5) | 318 (77.6) | 285 (82.4) | 274 (91.6) |
| 0 | 142 (28.3) | 184 (44.9) | 168 (48.6) | 162 (54.2) |
| Maintenance of OGC dose from 6 months post-index, mg/day,% (n/N*) | ||||
| ≤10 | - | 97.0 (355/366) | 95.5 (298/312) | 98.9 (271/274) |
| ≤7.5 | - | 92.9 (261/281) | 93.8 (227/242) | 96.8 (212/219) |
| ≤5 | - | 91.8 (235/256) | 92.7 (203/219) | 95.9 (189/197) |
| 0 | - | 92.1 (105/114) | 87.1 (81/93) | 90.5 (76/84) |
*Decreased over time due to loss-to-follow-up.